Evotec acquires Kinaxo Biotechnologies
Kinaxo’s acquisition establishes Evotec‘s as an integrated drug discovery and early development partner for pharma and biotechnology companies. Kinaxo’s novel technologies are expected to help Evotec arrive at
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Circassia said PAP-1, a novel topical therapeutic for psoriasis and atopic dermatitis, is a highly specific immunosuppressant and a selective Kv1.3 inhibitor that has ideal topical delivery characteristics.